Mitchell S. Cairo, MD | Authors

Dose Reductions and Delays: Limitations of Myelosuppressive Chemotherapy

September 01, 2000

Thrombocytopenia occurs at various grades of severity in patients with nonmyeloid malignancies undergoing chemotherapy with myelosuppressive agents. Frequently, it is the major dose-limiting hematologic toxicity, especially in the treatment of potentially curable malignancies such as leukemia, lymphomas, and pediatric cancers.